Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Department of Oncology, the First Affiliated Hospital of NanChang University, NanChang, China.
Clin Transl Med. 2024 Oct;14(10):e70061. doi: 10.1002/ctm2.70061.
Combinatory therapeutic strategy containing immunochemotherapy as part of induction therapy components is one of the current trends in the treatment of high-risk metastatic locally advanced nasopharyngeal carcinoma (NPC). However, the mechanism underlying the heterogeneity of response at the single-cell level has not been underexplored.
18 bulks and 11 single-cell RNA sequencing from paired before-treatment and on-treatment samples in patients with treatment-naive high-risk metastatic locally advanced NPCs were obtained. Following quality control, a total of 87 191 cells were included in the subsequence bioinformatics analysis.
Immunochemotherapy was associated with on-treatment tumour microenvironment (TME) remodelling, including upregulation of anti-TMEs signatures, downregulation of pro-TMEs signatures, reversing CD8 T exhaustion, and repolarizing proinflammatory TAMs. For the patients achieving a complete response, the cytotoxic activity of CD8 T cells was stimulated and more interferon-gamma was provided, which would be the key for TAMs proinflammatory repolarization and eventually promote the CD8 T cells maturation in turn. Among patients who did not reach complete response, differentiation and hypoxia signatures for endothelial cells were elevated after therapy. These patients exhibited higher levels of immune checkpoint genes in malignant cells at the baseline (before treatment), and decreased tumour antigen presentation activity, which may underlie the resistance mechanism to therapy.
This study pictures a map of TME modulation following immunochemotherapy-based combination induction therapy and provides potential future approaches.
Immunochemotherapy remodeled T cell phenotypes. For the patients achieving complete response, more interferon gamma was provided by CD8 T cells after therapy, which would be the key for TAMs pro-inflammatory repolarization and eventually promote the CD8 T cells maturation in turns. Among patients who did not reach complete response, malignant cells exhibited higher level of immune checkpoint genes before therapy, and decreased tumor antigen presentation activity, which may underlie the resistance mechanism to therapy.
免疫化疗联合治疗策略作为诱导治疗的一部分,是治疗高危转移性局部晚期鼻咽癌(NPC)的当前趋势之一。然而,在单细胞水平上,反应异质性的潜在机制尚未得到充分探索。
从未经治疗的高危转移性局部晚期 NPC 患者的治疗前和治疗期间的配对样本中获得了 18 个 bulk 和 11 个单细胞 RNA 测序。经过质量控制,共有 87191 个细胞被纳入后续的生物信息学分析。
免疫化疗与治疗中的肿瘤微环境(TME)重塑有关,包括抗 TME 特征的上调、促 TME 特征的下调、CD8 T 细胞衰竭的逆转以及促炎 TAMs 的极化。对于达到完全缓解的患者,CD8 T 细胞的细胞毒性活性得到了刺激,并且提供了更多的干扰素-γ,这将是 TAMs 促炎极化的关键,进而促进 CD8 T 细胞的成熟。在未达到完全缓解的患者中,治疗后内皮细胞的分化和缺氧特征升高。这些患者在基线(治疗前)时恶性细胞中免疫检查点基因水平较高,肿瘤抗原呈递活性降低,这可能是治疗耐药的潜在机制。
本研究描绘了基于免疫化疗的联合诱导治疗后 TME 调节的图谱,并提供了潜在的未来方法。
免疫化疗重塑了 T 细胞表型。对于达到完全缓解的患者,治疗后 CD8 T 细胞提供了更多的干扰素-γ,这将是 TAMs 促炎极化并最终促进 CD8 T 细胞成熟的关键。在未达到完全缓解的患者中,治疗前恶性细胞中免疫检查点基因水平较高,肿瘤抗原呈递活性降低,这可能是治疗耐药的潜在机制。